comparemela.com

Latest Breaking News On - Bispecific antibodies - Page 10 : comparemela.com

Bispecific Antibodies in DLBCL: Therapeutic Potential

Robert Mancini, PharmD, discusses current DLBCL (diffuse large B cell lymphoma) management approaches, relapse rates, frontline, and subsequent therapies, including emerging treatments like bispecific T-cell engagers and monoclonal antibodies.

Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and Bispecifics

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.